{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-045309","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.695983+00:00","generated_at":"2026-05-22T10:16:03.650841+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Positive topline results from VIRAGE Phase 2b trial: VCN-01+SoC improves OS, PFS, DoR in metastatic pancreatic cancer","bullets":["Median OS 10.8 vs 8.6 months for VCN-01+SoC vs SoC alone (HR=0.57, p=0.0546).","Median PFS 7.0 vs 4.6 months (HR=0.55, p=0.0105).","Median DoR doubled to 11.2 vs 5.4 months (HR=0.22, p=0.0035).","2-dose VCN-01 + ≥4 cycles SoC subgroup: median OS 14.8 vs 11.6 months (HR=0.44, p=0.046).","Safety met primary endpoint; AEs transient/reversible, consistent with prior trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-045309","json":"https://secwatch.observer/filing/0001104659-25-045309.json","markdown":"https://secwatch.observer/filing/0001104659-25-045309.md","text":"https://secwatch.observer/filing/0001104659-25-045309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465925045309/0001104659-25-045309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465925045309/tm2514050d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T10:16:03.650841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}